GEN Exclusives

More »

Best of the Web

More »
Oct 15, 2009 (Vol. 29, No. 18)

FunDO

URL:django.nubic.northwestern.edu/fundo
  • Easy to use, provides tutorial and example analysis
  • It would be nice to include links to literature citations

With a name that rolls off the tongue, FunDO (whose unabridged name is Exploring Genes Using FUNctional Disease Ontology Annotation) is a tool to help understand human disease. Developed at the Northwestern University Biomedical Informatics Center, this resource aims to facilitate the passage of knowledge from the laboratory to the clinic. In today’s world of high-throughput assays, it is not the acquisition of knowledge that is the problem. Sure, anybody can submit RNA to the core facility for microarray analysis, but when the sizable spreadsheet with the data is returned, then what? Using FunDO, scientists can input a list of genes, such as that from a microarray, and receive a diagram with the diseases to which their genes most map. In this, lists of genes are transformed into clustered, targeted results. The site offers a comprehensive tutorial as well as an example list of genes and analysis. FunDO is free, easy-to-use, and is a great place to start for anybody investigating genes and disease.

  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?